A. Nosari, A. Tedeschi, F. Ricci, M. Montillo. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008;93(2):e30-e31; https://doi.org/10.3324/haematol.12465.